JournalsHub
.online
Find My Journal
JL

J Lüdemann

Centre for Advanced Study BG

36
Publications
886
Citations
7
H-Index
6
i10-Index
1.33
2yr Mean Cite
-
Cite/Paper
Data combined from OpenAlex . OA = OpenAlex S2 = Semantic Scholar
Verify on Google Scholar

Publication & Citation Trends

Most Cited Works

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial
Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay, J Lüdemann, Camilla Andreassen +2 more
The Lancet Diabetes & Endocrinology 2018
739
Ibuprofen sodium dihydrate, an ibuprofen formulation with improved absorption characteristics, provides faster and greater pain relief than ibuprofen acid
Peter Schleier, A. Prochnau, Andrea Maria Schmidt‐Westhausen, Harry P. F. Peters, Jürgen Becker +8 more
International Journal of Clinical Pharmacology and Therapeutics 2007
36
A randomized non‐inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with Type 2 diabetes experiencing inadequate glycaemic control on metformin and sitagliptin
Rafael Violante, Juliana H. Oliveira, Kun‐Ho Yoon, Victoria Reed, Miao Yu +3 more
Diabetic Medicine 2012
35
Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials OA
Vanita R. Aroda, Matthew Capehorn, Louis Chaykin, Juan P. Frías, Nanna L. Lausvig +7 more
Diabetes Obesity and Metabolism 2019
27
Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 <i>post hoc</i> analyses OA
Richard E. Pratley, Vanita R. Aroda, Andrei‐Mircea Catarig, Ildiko Lingvay, J Lüdemann +2 more
BMJ Open 2020
19

Publications

33 total

Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 <i>post hoc</i> analyses PDF

Richard E. Pratley, Vanita R. Aroda, Andrei‐Mircea Catarig, Ildiko Lingvay, J Lüdemann et al. - BMJ Open, 2020
Cited by 19 OpenAlex

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials PDF

Vanita R. Aroda, Matthew Capehorn, Louis Chaykin, Juan P. Frías, Nanna L. Lausvig et al. - Diabetes Obesity and Metabolism, 2019
Cited by 27 OpenAlex

87 - Efficacy and Safety of Semaglutide 0.5 mg vs Dulaglutide 1.5 mg Once Weekly in Type 2 Diabetes: Posthoc Analysis of SUSTAIN 7

Ronald Goldenberg, Richard E. Pratley, Vanita R. Aroda, Theis Gondolf, Thomas Fritz Hansen et al. - Canadian Journal of Diabetes, 2019
Cited by 1 OpenAlex

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial

Richard E. Pratley, Vanita R. Aroda, Ildiko Lingvay, J Lüdemann, Camilla Andreassen et al. - The Lancet Diabetes & Endocrinology, 2018
Cited by 739 OpenAlex

Semaglutide Provides Superior Body Weight Reduction Across Sustain 1–5 Clinical Trials PDF

Emanuela Cavalari, Ildiko Lingvay, J Lüdemann, Michel Marre, Kari Uusinarkaus et al. - International Journal of Nutrology, 2018
Cited by 0 OpenAlex

Liraglutid und renale Endpunkte bei Typ 2 Diabetes: Ergebnisse der LEADER Studie

J. Mann, MA Nauck, Stephan Jacob, J Lüdemann, Kirstine Brown‐Frandsen et al. - Diabetologie und Stoffwechsel, 2017
Cited by 3 OpenAlex

LEADER-5: Prävalenz und kardiometabolischer Einfluss von Übergewicht und Adipositas bei kardiovaskulären Hochrisikopatienten mit Typ 2 Diabetes mellitus: Baseline-Daten aus der LEADER-Studie

Simon N. Jacob, J Lüdemann, Mariana Rieck, LM Miquel, Stephen C. Bain - Diabetologie und Stoffwechsel, 2016
Cited by 0 OpenAlex

Erkenntnisse aus der LEADER-Studie

J Lüdemann, Stephan Jacob - Diabetes aktuell, 2016
Cited by 0 OpenAlex

Patient preference and tolerability of a DPP-4 inhibitor <i>versus</i> a GLP-1 analog in patients with type 2 diabetes mellitus inadequately controlled with metformin: a 24-week, randomized, multicenter, crossover study PDF

J Lüdemann, E D Dütting, Markus Dworak - Therapeutic Advances in Endocrinology and Metabolism, 2015
Cited by 11 OpenAlex

Tageszeitlich flexible Gabe von Insulin degludec bei Patienten mit Typ-1-Diabetes oder Typ-2-Diabetes

J Lüdemann, K Milek, Birgit Wilhelm, Alexander Segner, Elmar Jaeckel - MMW - Fortschritte der Medizin, 2014
Cited by 2 OpenAlex

Research Topics

Diabetes Treatment and Management (25) Diabetes Management and Research (16) Metabolism, Diabetes, and Cancer (9) Diabetes and associated disorders (7) Hyperglycemia and glycemic control in critically ill and hospitalized patients (4)

Frequent Co-Authors

VA
Vanita R. Aroda
4 joint publications
IL
Ildiko Lingvay
4 joint publications
RI
Richard E. Pratley
3 joint publications
AD
Adie Viljoen
3 joint publications
K
K Milek
3 joint publications
ST
Stephen C. Bain
2 joint publications

Affiliations

Universitätsmedizin Greifswald
DE 2006 - 2006
Diabetes Australia
AU 2019 - 2019
Concord Consortium
US 2019 - 2019
Universität Greifswald
DE 2008 - 2008
Center for Clinical Studies
US 2017 - 2017

External Profiles

OpenAlex Profile Search Semantic Scholar Google Scholar

Share Profile

Back to Researchers
Comparison Shortlist
0 journals
Est. APC Budget: $0
Compare Now